A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
12/2011
12/22/2011	US20110313026 Dna and proteins or peptides specific of bacteria of the neisseria meningitidis species, methods for obtaining them and biological applications thereof
12/22/2011	US20110311617 Oral vaccine
12/22/2011	US20110311615 Novel gp41 antigens
12/22/2011	US20110311614 Splitting gp41
12/22/2011	US20110311612 Humanized Neuraminidase Antibody and Methods of Use Thereof
12/22/2011	US20110311594 Controlled release compositions with reduced food effect
12/22/2011	US20110311590 Compositions for treating an allergic or asthmatic condition
12/22/2011	US20110311589 Compositions and dosage regimes comprising a clostridial vaccine and levamisole
12/22/2011	US20110311588 Agents and treatment for snoring and respiratory effort related arousals in sleep
12/22/2011	US20110311587 Fusogenic virus-like particles and uses thereof
12/22/2011	US20110311586 Materials and methods for respiratory disease control in canines
12/22/2011	US20110311585 Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
12/22/2011	US20110311583 Novel lipids and compositions for the delivery of therapeutics
12/22/2011	US20110311582 Novel lipids and compositions for the delivery of therapeutics
12/22/2011	US20110311581 Reverse genetics of negative-strand rna viruses in yeast
12/22/2011	US20110311580 Settings for recombinant adenoviral-based vaccines
12/22/2011	US20110311579 Flaviviruses expressing the prM, E, and NS1 proteins of other flaviviruses and uses thereof
12/22/2011	US20110311578 Recombinant inactivated viral vector vaccine
12/22/2011	US20110311577 Method of producing a vaccine
12/22/2011	US20110311576 Mixing lyophilised meningococcal vaccines with non-hib vaccines
12/22/2011	US20110311575 MIXING LYOPHILISED MENINGOCOCCAL VACCINES WITH D-T-Pa VACCINES
12/22/2011	US20110311574 Multiple vaccination including serogroup c meningococcus
12/22/2011	US20110311573 Method for Preparing Recombinant Antigen Complex Using Rotavirus Nanoparticle
12/22/2011	US20110311572 Nucleotide and amino acid sequences encoding an exported protein 1 derived from plasmodium vivax and uses thereof
12/22/2011	US20110311571 Methods and compositions for treating and preventing malaria using an invasion ligand directed to a protease-resistant receptor
12/22/2011	US20110311570 Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species
12/22/2011	US20110311569 HIV-1 Peptides, Nucleic Acids, and Compositions and Uses Thereof
12/22/2011	US20110311568 Vaccine
12/22/2011	US20110311567 Immunogenically-Enhanced Polypeptides and Related Methods
12/22/2011	US20110311565 Phage Constructs, Sequences and Antigenic Compositions for Immunocontraception of Animals
12/22/2011	US20110311564 Method for Producing Intermediates for the Production of Novel Macrocycles that are Inhibitors of the Proteasomic Degradation of p27, such as Argyrin and Derivatives Thereof, and Uses of Said Macrocycles
12/22/2011	US20110311563 Synthetic Antigenic Peptides and Lipopeptides Derived from Mycobacterium Avium Subsp. Paratubuerculosis
12/22/2011	US20110311560 Methods and Compositions Relating to CCR5 Antagonist, IFN-Gamma and IL-13 Induced Inflammation
12/22/2011	US20110311558 Recombinant Bone Marrow Stromal Antigen-2 in the Treatment of Autoimmune Diseases
12/22/2011	US20110311557 Reciprocal serum/plasma exchange for the treatment of cancer
12/22/2011	US20110311556 Anti-rhesus d monoclonal antibody
12/22/2011	US20110311555 Tc11 as a Transcriptional Regulator
12/22/2011	US20110311554 Compositions and Methods for Suppressing Fibrocytes
12/22/2011	US20110311553 Effectors of PAR-2 Activation and Their Use in the Modulation of Inflammation
12/22/2011	US20110311552 Notch1 receptor binding agents and methods of use thereof
12/22/2011	US20110311551 Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions
12/22/2011	US20110311550 Agents for hcv treatment
12/22/2011	US20110311549 Methods for treating conditions associated with masp-2 dependent complement activation
12/22/2011	US20110311548 Use of b lymphocyte stimulator protein antagonists to treat asthma and other allergic and inflammatory conditions of the respiratory system
12/22/2011	US20110311547 Arthritis Treatment
12/22/2011	US20110311546 Angiopoietin-2 specific binding agents
12/22/2011	US20110311545 Family of pain producing substances and methods to produce novel analgesic drugs
12/22/2011	US20110311544 Anti-cd71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells
12/22/2011	US20110311543 Tumor Antigens BFA5 for Prevention and/or Treatment of Cancer
12/22/2011	US20110311542 Sp35 Antibodies and Uses Thereof
12/22/2011	US20110311541 Mutant proteins of the f protein of piv-5 and piv-2
12/22/2011	US20110311540 Wisp polypeptides and nucleic acids encoding same
12/22/2011	US20110311539 Diagnosis and treatment of cancer using cancer-testis antigens
12/22/2011	US20110311538 Inhibitors of receptor tyrosine kinases and methods of use thereof
12/22/2011	US20110311537 Methods of using il-1 antagonists to treat familial mediterranean fever (fmf)
12/22/2011	US20110311536 Prevention of type 1 diabetes by treg vaccination with an insulin mimetope
12/22/2011	US20110311535 Nkg2d-fc for immunotherapy
12/22/2011	US20110311534 Wnt antagonists and their use in the diagnosis and treatment of wnt-mediated disorders
12/22/2011	US20110311533 Regulation of protein level
12/22/2011	US20110311532 Inhibition of complement and cellular activation
12/22/2011	US20110311531 Immunotherapy of autoimmune disorders using antibodies which target b-cells
12/22/2011	US20110311530 Truncated baff receptors
12/22/2011	US20110311529 Method for treating a rheumatic disease using a soluble tla4 molecule
12/22/2011	US20110311528 Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of psoriasis
12/22/2011	US20110311527 IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
12/22/2011	US20110311526 Polynucleotide and polypeptide sequences involved in the process of bone remodeling
12/22/2011	US20110311525 Delivery of a cd40 agonist to a tumor draining lymph node of a subject
12/22/2011	US20110311524 Inhibitors of Angiopoietin-Like 4 Protein, Combinations, and Their Use
12/22/2011	US20110311523 Platelet derived growth factor receptor supports cytomegalovirus infectivity
12/22/2011	US20110311522 Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
12/22/2011	US20110311521 Novel therapy for anxiety
12/22/2011	US20110311520 Methods for treatment of allergic asthma
12/22/2011	US20110311519 Methods of treatment of bone degenerative diseases
12/22/2011	US20110311518 Novel synthetic agonists of tlr9
12/22/2011	US20110311517 Antibodies and methods for treating estrogen receptor-associated diseases
12/22/2011	US20110311516 Chemically Programmed Vaccination
12/22/2011	US20110311515 Pulmonary administration of immunoglobulin single variable domains and constructs thereof
12/22/2011	US20110311514 Methods for treating disorders of amino acid metabolism
12/22/2011	US20110311513 Methods for treating coagulation disorders
12/22/2011	US20110311512 Genetic Variants Underlying Human Cognition and Methods of Use Thereof as Diagnostic and Therapeutic Targets
12/22/2011	US20110311485 1,2,4-oxadiazole derivatives and their therapeutic use
12/22/2011	US20110311483 Crth2 modulators
12/22/2011	US20110311479 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
12/22/2011	US20110311478 Combinatorial Methods For Treating Cellular Proliferative Disorders And Immune Deficiencies Using Salicinium
12/22/2011	US20110311477 Infusion Treatment Methods And Compositions Using Salicinium For Treating Cellular Proliferative Disorders And Immune Deficiencies
12/22/2011	US20110311476 Methods For Treating An Immune Deficiency Or Enhancing Immune Function Using Salicinium, Non-Limited In Terms Of Treatment Indication, But Encompassing Methods For Treating Cancer And Microbial, Bacterial, Viral, Fungal; Non-Limited In Terms of Delivery Mode, Formulation
12/22/2011	US20110311474 Novel Tricyclic Compounds
12/22/2011	US20110311472 Application of mrna for use as a therapeutic against tumour diseases
12/22/2011	US20110311454 Molecules with extended half-lives, compositions and uses thereof
12/22/2011	US20110311450 Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
12/22/2011	US20110311449 Antibodies
12/22/2011	US20110311448 Antibody to rage and uses for in vivo imaging or for targeting therapy
12/22/2011	US20110311445 Diagnosis and treatment of myeloid and lymphoid cell cancers
12/22/2011	US20110311443 Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
12/22/2011	CA2839421A1 Antibodies useful in passive influenza immuization
12/22/2011	CA2839420A1 High affinity human antibodies to human cytomegalovirus (cmv) gb protein
12/22/2011	CA2825986A1 Arthritis treatment
12/22/2011	CA2802857A1 Antibodies to endoplasmin and their use
12/22/2011	CA2802631A1 S100a4 antibodies and therapeutic uses thereof
12/22/2011	CA2802599A1 Modified parvovirus having enhanced anti-tumour efficacy

1 ... 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 ... 1823